p53-abnormal endometrial cancer, including uterine serous carcinoma

What changed: p53-abnormal endometrial cancer, including uterine serous carcinoma

Cancer page →

Every dated change on the records linked to p53-abnormal endometrial cancer, including uterine serous carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result4Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordp53-abnormal endometrial cancer, including uterine serous carcinoma
Facts on this page last checked
When this page itself was last checked or edited.

2024 · 1

2024MilestoneTrastuzumab deruxtecan
Trastuzumab deruxtecan approved for HER2 3+ solid tumours after DESTINY-PanTumor02
A milestone in how this cancer is treated.

2023 · 2

2021 · 1

2021Trial resultKEYNOTE-775 / Study 309
KEYNOTE-775 / Study 309 reported
OS 18.

2020 · 1

2020MilestonePORTEC-3
PORTEC-3 molecular analysis: chemotherapy benefit concentrated in p53-abnormal tumours
A milestone in how this cancer is treated.

2018 · 3

2013 · 1

2013MilestoneEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
TCGA defines the copy-number-high, serous-like class
A milestone in how this cancer is treated.

1982 · 1

1982Milestonep53-abnormal endometrial cancer, including uterine serous carcinoma
Hendrickson describes uterine papillary serous carcinoma as a distinct aggressive type
A milestone in how this cancer is treated.